ARS Pharmaceuticals (SPRY) Names Donn Casale as New CEO

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) appointed Donn Casale as CEO, effective July 7, succeeding co-founder Richard Lowenthal, who left the company on July 6. Casale has over 25 years of experience in biopharma, including previous roles at Dynavax Technologies, where he helped grow annual revenues for the HEPLISAV-B vaccine to over $300 million. Additionally, on June 24, the company reported no new coverage decisions for its epinephrine nasal spray, neffy, during the July 1 formulary cycle. This leadership transition may impact the company's strategic direction and market opportunities for neffy.